Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. entered into a settlement agreement with Novartis Pharma AG which involves a stipulation of dismissal of the lawsuits in the United States relating to the Abbreviated New Drug Applications filed by Dr. Reddy's for a generic version of rivastigmine tartrate capsules sold under the trade-name Exelon. Under the terms of the agreement, Dr. Reddy's will not launch its generic Rivastigmine Tartrate capsules until sometime before the expiry of the Orange Book patents claiming Rivastigmine.